A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialed by clinicians and ...
Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...
Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.
The company, which secured $200 million from investors in a private funding deal last week, learned Tuesday of a serious side ...
Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...
In a new study, a team of researchers, including Anneliene Jonker, has published, in Nature Reviews Drug Discovery, the first ...
Neurogene ( NGNE, Financials) shares fell 35% in Tuesday's pre-market trading following the release of interim results from a ...
When looking at Neurogene’s stock performance year-to-date, it’s hard to ignore the impressive +269.09% increase. However, this recent downturn suggests that the market is responding to something ...
Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...
A stunning image of the Wallace Monument at sunset has won a Redding photographer a national award. Thomas Lamont – known ...
A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialled by clinicians and researchers at UCL and Great Ormond Street Hospital (GOSH). The study, ...
The UK Government recently announced a new public-private collaboration to develop the world's first early warning system for ...